Pathways of Renal Fibrosis and Modulation of Matrix Turnover in Experimental Hypercholesterolemia

Dyslipidemia often accompanies and accelerates renal disease, partly by promoting fibrosis. However, the mechanisms mediating this effect are unclear. We hypothesized that hypercholesterolemia modulates several interlinked pathways that promote deposition and blunt degradation of extracellular matrix, and that these could be manipulated by reversal of hypercholesterolemia. Fourteen pigs were fed a 16-week 2% high-cholesterol diet (HC-HC; n=7) or normal diet (n=7), whereas in 7 others, a 10-week HC was followed by a 6-week normal diet (HC-N). Renal endothelial function was assessed in vivo with electron-beam computed tomography, and renal tissue was then studied ex vivo using Western blot, real-time quantitative polymerase chain reaction, gelatin zymography, and immunostaining. HC-HC kidneys showed endothelial dysfunction, accompanied by increased intrarenal oxidative stress, inflammation, activation of the endothelin and transforming-growth factor-&bgr; systems, and decreased matrix metalloproteinase expression and activity. Accordingly, HC-HC kidneys showed increased collagen IV expression and fibrosis. A lipid-lowering dietary intervention reversed most of these changes. In conclusion, this study indicates that renal fibrosis in early atherosclerosis is a result of a simultaneous increase in extracellular matrix deposition and blunted matrix metalloproteinase–mediated degradation, overall promoting perivascular and tubulointerstitial fibrosis. Notably, many of these pathways may be reversible in hypercholesterolemia, and crucial targets could potentially be identified for early interventions to preserve the kidney.

[1]  L. Lerman,et al.  Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia. , 2005, Journal of the American Society of Nephrology : JASN.

[2]  K. Nakao,et al.  The FASEB Journal express article 10.1096/fj.04-2183fje. Published online October 20, 2004. ©2004 FASEB , 2022 .

[3]  E. Ritz,et al.  Reversal of glomerular lesions involves coordinated restructuring of glomerular microvasculature. , 2004, Journal of the American Society of Nephrology : JASN.

[4]  R. Brandes,et al.  Role of Podocytes for Reversal of Glomerulosclerosis and Proteinuria in the Aging Kidney After Endothelin Inhibition , 2004, Hypertension.

[5]  Claudio Napoli,et al.  Antioxidant Intervention Attenuates Myocardial Neovascularization in Hypercholesterolemia , 2004, Circulation.

[6]  C. Napoli,et al.  Antioxidant intervention blunts renal injury in experimental renovascular disease. , 2004, Journal of the American Society of Nephrology : JASN.

[7]  L. Dworkin,et al.  Hepatocyte growth factor ameliorates progression of interstitial fibrosis in rats with established renal injury. , 2004, Kidney international.

[8]  Ying E. Zhang,et al.  Smad-dependent and Smad-independent pathways in TGF-β family signalling , 2003, Nature.

[9]  S. Kohno,et al.  Oxidative modulation of NF-κB signaling by oxidized low-density lipoprotein , 2003 .

[10]  Albert Hofman,et al.  Risk Factors for Progression of Atherosclerosis Measured at Multiple Sites in the Arterial Tree: The Rotterdam Study , 2003, Stroke.

[11]  C. Napoli,et al.  Endothelin-1 receptor blockade prevents renal injury in experimental hypercholesterolemia. , 2003, Kidney international.

[12]  Eric J Topol,et al.  Prevalence of conventional risk factors in patients with coronary heart disease. , 2003, JAMA.

[13]  C. Napoli,et al.  Mechanisms of Renal Structural Alterations in Combined Hypercholesterolemia and Renal Artery Stenosis , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[14]  H. Taylor,et al.  Lipid Abnormalities and Renal Disease: Is Dyslipidemia a Predictor of Progression of Renal Disease? , 2003, The American journal of the medical sciences.

[15]  C. Napoli,et al.  Lipid-lowering-independent effects of simvastatin on the kidney in experimental hypercholesterolaemia. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  H. Morawietz,et al.  NADPH oxidase in endothelial cells: impact on atherosclerosis. , 2003, Antioxidants & redox signaling.

[17]  T. Matsunaga,et al.  NF-κB activation in endothelial cells treated with oxidized high-density lipoprotein , 2003 .

[18]  Amir Lerman,et al.  Endothelial Dysfunction: A Marker of Atherosclerotic Risk , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[19]  L. Lerman,et al.  Angiotensin II AT1 receptor blockade improves renal perfusion in hypercholesterolemia. , 2003, American journal of hypertension.

[20]  T. Matsunaga,et al.  NF-kappa B activation in endothelial cells treated with oxidized high-density lipoprotein. , 2003, Biochemical and biophysical research communications.

[21]  S. Kohno,et al.  Oxidative modulation of NF-kappaB signaling by oxidized low-density lipoprotein. , 2003, Biochemical and biophysical research communications.

[22]  R. Derynck,et al.  Smad-dependent and Smad-independent pathways in TGF-beta family signalling. , 2003, Nature.

[23]  J. Grande,et al.  Transforming Growth Factor- Signal Transduction and Progressive Renal Disease , 2002 .

[24]  E. Bottinger,et al.  TGF-β signaling in renal disease , 2002 .

[25]  C. Napoli,et al.  Distinct Renal Injury in Early Atherosclerosis and Renovascular Disease , 2002, Circulation.

[26]  T. Katagiri,et al.  Antioxidant N-acetylcysteine inhibits vasoactive agents-potentiated mitogenic effect of mildly oxidized LDL on vascular smooth muscle cells. , 2002, Hypertension research : official journal of the Japanese Society of Hypertension.

[27]  R. Brandes,et al.  Native LDL Induces Proliferation of Human Vascular Smooth Muscle Cells via Redox-Mediated Activation of ERK 1/2 Mitogen-Activated Protein Kinases , 2002, Hypertension.

[28]  V. Ferrans New insights into the world of matrix metalloproteinases. , 2002, Circulation.

[29]  E. Ritman,et al.  Simvastatin Preserves the Structure of Coronary Adventitial Vasa Vasorum in Experimental Hypercholesterolemia Independent of Lipid Lowering , 2002, Circulation.

[30]  J. Grande,et al.  Transforming growth factor-beta signal transduction and progressive renal disease. , 2002, Experimental biology and medicine.

[31]  M. Bitzer,et al.  TGF-beta signaling in renal disease. , 2002, Journal of the American Society of Nephrology : JASN.

[32]  L. Lerman,et al.  Pathophysiology of ischemic nephropathy. , 2001, The Urologic clinics of North America.

[33]  E. Ritman,et al.  Noninvasive measurement of concurrent single-kidney perfusion, glomerular filtration, and tubular function. , 2001, American journal of physiology. Renal physiology.

[34]  C. Napoli,et al.  Multiple role of reactive oxygen species in the arterial wall , 2001, Journal of cellular biochemistry.

[35]  P. Bornstein,et al.  Thrombospondins as matricellular modulators of cell function. , 2001, The Journal of clinical investigation.

[36]  P. Sheedy,et al.  Combination of Hypercholesterolemia and Hypertension Augments Renal Function Abnormalities , 2001, Hypertension.

[37]  C. Napoli,et al.  Increased Oxidative Stress in Experimental Renovascular Hypertension , 2001, Hypertension.

[38]  P. Ronco,et al.  Do matrix metalloproteinases MMP-2 and MMP-9 (gelatinases) play a role in renal development, physiology and glomerular diseases? , 2001, Current opinion in nephrology and hypertension.

[39]  L. Lerman,et al.  Impaired renal vascular endothelial function in vitro in experimental hypercholesterolemia. , 2001, Atherosclerosis.

[40]  A. Eddy Molecular basis of renal fibrosis , 2000, Pediatric Nephrology.

[41]  M. Simons,et al.  Thrombospondin Type 1 Repeats Interact with Matrix Metalloproteinase 2 , 2000, The Journal of Biological Chemistry.

[42]  R. Evans,et al.  Diversity of responses of renal cortical and medullary blood flow to vasoconstrictors in conscious rabbits. , 2000, Acta physiologica Scandinavica.

[43]  J. Coresh,et al.  Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. , 2000, Kidney international.

[44]  T. Kita,et al.  Transforming Growth Factor-β1 Increases the Expression of Lectin-like Oxidized Low-Density Lipoprotein Receptor-1 , 2000 .

[45]  W. Keane,et al.  The role of lipids in renal disease: future challenges. , 2000, Kidney international. Supplement.

[46]  W. Stetler-Stevenson,et al.  Matrix metalloproteinases in renal development and disease. , 2000, Journal of the American Society of Nephrology : JASN.

[47]  L. Lerman,et al.  In vivo renal vascular and tubular function in experimental hypercholesterolemia. , 1999, Hypertension.

[48]  P. Sheedy,et al.  Noninvasive evaluation of a novel swine model of renal artery stenosis. , 1999, Journal of the American Society of Nephrology : JASN.

[49]  Magil Ab INTERSTITIAL FOAM CELLS AND OXIDIZED LIPOPROTEIN IN HUMAN GLOMERULAR DISEASE , 1999 .

[50]  A. Magil Interstitial foam cells and oxidized lipoprotein in human glomerular disease. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[51]  H. van Goor,et al.  Oxidized LDL stimulates the expression of TGF-beta and fibronectin in human glomerular epithelial cells. , 1997, Kidney international.

[52]  A. Eddy Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolemia. , 1996, Kidney international.

[53]  B. Kasiske,et al.  Early glomerular changes in rats with dietary-induced hypercholesterolemia. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[54]  James P. Quigley,et al.  Matrix Metalloproteinase-2 Is an Interstitial Collagenase , 1995, The Journal of Biological Chemistry.

[55]  A. Strongin,et al.  Mechanism Of Cell Surface Activation Of 72-kDa Type IV Collagenase , 1995, The Journal of Biological Chemistry.

[56]  J. Quigley,et al.  Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. , 1995, The Journal of biological chemistry.

[57]  P. Libby,et al.  Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. , 1994, The Journal of clinical investigation.

[58]  M. Sporn,et al.  Transforming growth factor beta. , 1988, Advances in cancer research.